why choose us

300×250 Ad Slot

Drug FDA Status

Showing 70 of 161 result(s) (Page 7 of 17)
Drug Name: Crenessity

Active Ingredient: crinecerfont

Approval Date: 2024-12-13

Description: To treat classic congenital adrenal hyperplasia 
Press Release

Drug Name: Unloxcyt

Active Ingredient: cosibelimab-ipdl

Approval Date: 2024-12-13

Description: To treat cutaneous squamous cell carcinoma

Drug Name: Bizengri

Active Ingredient: zenocutuzumab-zbco

Approval Date: 2024-12-04

Description: To treat non-small cell lung cancer and pancreatic adenocarcinoma 

Drug Name: Iomervu

Active Ingredient: iomeprol

Approval Date: 2024-11-27

Description: For use as a radiographic contrast agent

Drug Name: Rapiblyk

Active Ingredient: landiolol

Approval Date: 2024-11-22

Description: To treat supraventricular tachycardia

Drug Name: Attruby

Active Ingredient: acoramidis

Approval Date: 2024-11-22

Description: To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
Drug Trials Snapshot

Drug Name: Ziihera

Active Ingredient: zanidatamab-hrii

Approval Date: 2024-11-20

Description: To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
Drug Trials Snapshot

Drug Name: Revuforj

Active Ingredient: revumenib

Approval Date: 2024-11-15

Description: To treat relapsed or refractory acute leukemia

Drug Name: Orlynvah

Active Ingredient: sulopenem etzadroxil, probenecid

Approval Date: 2024-10-25

Description: To treat uncomplicated urinary tract infections (uUTI)
Drug Trial Snapshot

Drug Name: Vyloy

Active Ingredient: zolbetuximab-clzb

Approval Date: 2024-10-18

Description: To treat gastric or gastroesophageal junction adenocarcinoma
Drug Trials Snapshots: VYLOY

300×250 Ad Slot